A Phase 1 interventional study of Adrixetinib in Chronic Graft-Versus-Host Disease, sponsored by Qurient Co., Ltd.. Recruiting at 8 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-30.
Sponsored by Qurient Co., Ltd. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 60 studies in Bronchiolitis Obliterans Syndrome with a site in Spain — 11 open to participants now, 17 under way, 6 of them phase 3. Bronchiolitis Obliterans Syndrome · Spain.
Among the 60 studies in Bronchiolitis Obliterans Syndrome with a site in Spain, this one is the 50th largest by planned enrollment of the 56 interventional ones that give a count, is one of 5 that started in 2025, is one of 2 in phase 1, reaches primary completion later than 14 of the 16 other live ones, and was the 55th registered.
714 studies on the registry are indexed under Bronchiolitis Obliterans Syndrome; 128 are open to participants now.
Browse Bronchiolitis Obliterans Syndrome studies →11 of the 60 studies in Bronchiolitis Obliterans Syndrome with a site in Spain are open now. Recruiting first, the newest first:
Sanofi · Sites in Spain, Netherlands
Ages 12+
Incyte Corporation · Sites in Spain, United States, Belgium and 3 more countries
Ages 2–17
Novartis Pharmaceuticals · Sites in Spain, United States, Australia and 14 more countries
Ages 1–18
Sanofi · Sites in Spain, United States, Belgium and 10 more countries
Ages 1–18
Dompé Farmaceutici S.p.A · Sites in Spain, United States, Italy
Ages 10–65
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 100 Bronchiolitis Obliterans Syndrome studies recruiting now, 45 (45%) set no upper age limit and 45 (45%) stop at 75 or younger; 25 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
60 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 23 · Phase 3 20 · Phase 4 5
First in 2002; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 18 is below the median of 50 across 565 interventional studies indexed under Bronchiolitis Obliterans Syndrome.
Median enrollment 129 across the 56 interventional studies, 324 across the 4 observational. Of the 40 that completed or were terminated, 24 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 60 have an industry lead sponsor. The 10 most frequent:
Qurient Co., Ltd. is the lead sponsor of 10 studies on the registry; 2 are open to participants now.
Qurient Co., Ltd. has 1 study filed under Bronchiolitis Obliterans Syndrome — fewer than ten, so there is no comparison to draw.
4 of the studies in Bronchiolitis Obliterans Syndrome with a site in Spain that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01804686Phase 3Janssen Research & Development, LLCA Long-term Extension Study of PCI-32765 (Ibrutinib) | 2026-12-31 |
| NCT07395232Phase 3Dompé Farmaceutici S.p.AAn Efficacy and Safety Study of DFL24498 in the Treatment of AKC | 2027-03 |
| NCT06585774Phase 3Incyte CorporationA Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease | 2027-09-28 |
| NCT06873308IRCCS Sacro Cuore Don Calabria di NegrarAssessment of Infection Activity in Travelers and Migrants Diagnosed With Chronic Schistosomiasis | 2027-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 60 studies in Bronchiolitis Obliterans Syndrome with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Open-label, dose escalation study to evaluate safety, tolerability pharmacokinetic and pharmacodynamic activity, and efficacy of Adrixetinib (Q702) in subjects with relapsed or refractory active chronic graft-versus-host disease (cGVHD).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Escalating doses of adrixetinib in 28 day cycles.
Drug: Adrixetinib
Administered orally
Also known as: Q702
Number of Participants with Dose-Limiting Toxicities (DLTs)
DLTs assessed for each dose level
Time frame: Cycle 1 (28 Days)
Number of Participants with Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs)
AEs and SAEs assessed for each dose level.
Time frame: Cycle 1 (28 Days)
Pharmacokinetics (PK)
Maximum Observed Plasma Concentration (Cmax), area under the curve AUC of Q702 and its primary metabolites
Time frame: Estimated up to Cycle 1 (28 Days)
Objective Response Rate (ORR)
Proportion of subjects with CR or PR by Cycle 7 Day 1 using Organ-specific response rate based on 2014 NIH Consensus Development Project on Criteria for Clinical Trials in cGVHD
Time frame: Cycle 7 Day 1 (One Cycle is 28 Days)
Duration of Response (DOR)
DOR defined as the time from best response of PR or CR until documented progression of cGVHD, start of new therapy, or death for any reason
Time frame: First CR or PR until documented PD, start of new therapy or death (Estimated up to 24 months)
Failure-Free Survival (FFS)
FFS is defined as the time from study enrollment (first date of Q702 treatment) to addition of another systemic therapy for cGVHD, relapse of underlying malignancy, or death whichever is earlier.
Time frame: Baseline to, whichever occurs first of, PD, Addition of Systemic Immune Suppressive Therapy, or Death due to Any Cause (Estimated up to 24 months)
Plan to share: Undecided
No publications or documents are linked to this record.
Started Dec 2025 (actual). Primary completion is estimated for Oct 2029, 46 months after the start.
Of 22 phase 1 interventional studies under Bronchiolitis Obliterans Syndrome, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 65. This study's planned 46 months is close to that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Adrixetinib
Bronchiolitis Obliterans Syndrome →
Qurient Co., Ltd.